Logo image of RLYB

RALLYBIO CORP (RLYB) Stock Price, Quote, News and Overview

NASDAQ:RLYB - Nasdaq - US75120L1008 - Common Stock - Currency: USD

0.25  0 (-0.71%)

After market: 0.2592 +0.01 (+3.68%)

RLYB Quote, Performance and Key Statistics

RALLYBIO CORP

NASDAQ:RLYB (4/17/2025, 8:00:02 PM)

After market: 0.2592 +0.01 (+3.68%)

0.25

0 (-0.71%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High2
52 Week Low0.22
Market Cap10.40M
Shares41.61M
Float36.90M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/bmo
IPO07-29 2021-07-29


RLYB short term performance overview.The bars show the price performance of RLYB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

RLYB long term performance overview.The bars show the price performance of RLYB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of RLYB is 0.25 USD. In the past month the price decreased by -64.29%. In the past year, price decreased by -85.8%.

RALLYBIO CORP / RLYB Daily stock chart

RLYB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.09 306.02B
AMGN AMGEN INC 13.99 149.08B
GILD GILEAD SCIENCES INC 22.68 130.32B
VRTX VERTEX PHARMACEUTICALS INC 1686.55 125.74B
REGN REGENERON PHARMACEUTICALS 12.34 61.56B
ARGX ARGENX SE - ADR 318.82 36.40B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 30.51B
ONC BEIGENE LTD-ADR N/A 24.89B
BNTX BIONTECH SE-ADR N/A 23.74B
NTRA NATERA INC N/A 20.02B
SMMT SUMMIT THERAPEUTICS INC N/A 18.15B
BIIB BIOGEN INC 7.2 17.36B

About RLYB

Company Profile

RLYB logo image Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. The company is headquartered in New Haven, Connecticut. The company went IPO on 2021-07-29. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.

Company Info

RALLYBIO CORP

234 Church Street, Suite 1020

New Haven CONNECTICUT US

CEO: Martin W. Mackay

Employees: 25

Company Website: https://rallybio.com/

Investor Relations: https://investors.rallybio.com/

Phone: 12038593820

RALLYBIO CORP / RLYB FAQ

What is the stock price of RALLYBIO CORP today?

The current stock price of RLYB is 0.25 USD. The price decreased by -0.71% in the last trading session.


What is the ticker symbol for RALLYBIO CORP stock?

The exchange symbol of RALLYBIO CORP is RLYB and it is listed on the Nasdaq exchange.


On which exchange is RLYB stock listed?

RLYB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for RALLYBIO CORP stock?

11 analysts have analysed RLYB and the average price target is 8.41 USD. This implies a price increase of 3266% is expected in the next year compared to the current price of 0.25. Check the RALLYBIO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is RALLYBIO CORP worth?

RALLYBIO CORP (RLYB) has a market capitalization of 10.40M USD. This makes RLYB a Nano Cap stock.


How many employees does RALLYBIO CORP have?

RALLYBIO CORP (RLYB) currently has 25 employees.


Is RALLYBIO CORP (RLYB) expected to grow?

The Revenue of RALLYBIO CORP (RLYB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the RLYB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy RALLYBIO CORP (RLYB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does RALLYBIO CORP (RLYB) stock pay dividends?

RLYB does not pay a dividend.


When does RALLYBIO CORP (RLYB) report earnings?

RALLYBIO CORP (RLYB) will report earnings on 2025-05-13, before the market open.


What is the Price/Earnings (PE) ratio of RALLYBIO CORP (RLYB)?

RALLYBIO CORP (RLYB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.35).


What is the Short Interest ratio of RALLYBIO CORP (RLYB) stock?

The outstanding short interest for RALLYBIO CORP (RLYB) is 0.92% of its float. Check the ownership tab for more information on the RLYB short interest.


RLYB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

RLYB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to RLYB. No worries on liquidiy or solvency for RLYB as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

RLYB Financial Highlights

Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -1.35. The EPS increased by 26.63% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -84.83%
ROE -93.71%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%N/A
EPS 1Y (TTM)26.63%
Revenue 1Y (TTM)N/A

RLYB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to RLYB. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 18.06% and a revenue growth -100% for RLYB


Ownership
Inst Owners69.98%
Ins Owners2.32%
Short Float %0.92%
Short Ratio5.59
Analysts
Analysts81.82
Price Target8.41 (3264%)
EPS Next Y18.06%
Revenue Next Year-100%